Qualigen Therapeutics, INC 8-K filings
8-K/A: Qualigen Therapeutics Appoints Graydon Bensler as Independent Director and Audit Committee Chair
Qualigen Therapeutics has amended its previous 8-K filing to include the correct director agreement and announced the appointment of Graydon Bensler as chairman of the audit committee.
Qualigen Therapeutics entered into an exchange agreement to convert a $1.1 million note into preferred stock and completed a $5.1 million private placement.
Qualigen Therapeutics has appointed Graydon Bensler, a financial professional, as an independent member of its Board of Directors, effective immediately.
Qualigen Therapeutics enacted a 1-for-50 reverse stock split of its common stock to comply with NASDAQ's minimum bid price requirement.
Qualigen Therapeutics will implement a 1-for-50 reverse stock split effective November 5, 2024, to increase its stock price and regain compliance with Nasdaq's minimum bid price requirement.
8-K: Qualigen Therapeutics Holds Annual Meeting, Approves Reverse Stock Split and Director Elections
Qualigen Therapeutics held its annual meeting on October 25, 2024, where shareholders voted on key proposals including the election of directors, ratification of auditors, a reverse stock split, and other corporate matters.
Qualigen Therapeutics received a notice from Nasdaq for not meeting the minimum independent director requirement on its audit committee following a board member's resignation.
Qualigen Therapeutics has appointed Braeden Lichti as an independent director and Robert Lim as the new Audit Committee chair, following the resignation of Matt Korenberg.
Qualigen Therapeutics experienced a significant leadership change with the immediate resignations of its CEO and CFO due to disagreements over the company's future direction.
Qualigen Therapeutics has been granted an extension by Nasdaq to maintain its listing, contingent on meeting all compliance criteria by November 19, 2024.
Qualigen Therapeutics successfully closed a public offering, raising approximately $3.47 million through the sale of common stock and pre-funded warrants.
Qualigen Therapeutics has priced a public offering of common stock and pre-funded warrants, expected to generate approximately $3.46 million in gross proceeds.
Qualigen Therapeutics has been given until October 31, 2024, to meet Nasdaq's minimum bid price and shareholder equity requirements to avoid delisting.
Qualigen Therapeutics has provided a $1.25 million loan to Marizyme Inc., secured by a promissory note with an 18% annual interest rate.
Qualigen Therapeutics has dismissed Baker Tilly US, LLP as its independent auditor and engaged WithumSmith+Brown, PC, effective July 11, 2024.
Qualigen Therapeutics has finalized a $2 million loan agreement with an institutional investor, resulting in a significant board restructuring.
Qualigen Therapeutics has entered into a securities purchase agreement for a $2 million loan, resulting in a significant change in the company's board of directors.
Qualigen Therapeutics has received a delisting notice from Nasdaq due to non-compliance with minimum bid price and stockholders' equity requirements, as well as a failure to file its quarterly report.
Marizyme and Qualigen have entered into a co-development agreement to commercialize Marizyme's DuraGraft product in the U.S., with Qualigen providing up to $1.5 million in funding.
Qualigen Therapeutics has terminated its license and sublicense agreement with Pan-RAS Holdings, effective March 16, 2024, without any liability to either party.
Qualigen Therapeutics has entered into a securities purchase agreement with Alpha Capital Anstalt, securing $500,000 in funding through a convertible debenture and warrants.
Qualigen Therapeutics has entered into a license and sublicense agreement with Pan-RAS Holdings, granting them exclusive rights to its renin-angiotensin system (RAS) drug development program for an upfront payment of $1 million and future royalties.